RRM1
ENSG00000167325
Target class
Enzyme
Chromosome
11
Approved drugs
5
Clinical candidates (approved and in development)
8
- Approved drugs
- 5
- Clinical candidates (approved and in development)
- 8
- Chemical probe available
- No
- Target name
- RRM1
- Gene name
- Ribonucleotide reductase catalytic subunit M1
- Gene symbol
- RRM1
- Protein name
- Ribonucleoside-diphosphate reductase large subunit (EC 1.17.4.1) (Ribonucleoside-diphosphate reductase subunit M1) (Ribonucleotide reductase large subunit)
- Gene biotype
- Protein coding
- Gene family
- Ribonucleotide reductase subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 104.05
- Tissue specificity (Gini)
- 0.346
- Tissue specificity (tau)
- 0.815
- KEGG gene identifiers
- hsa:6240
- Reactome pathways
- R-HSA-499943
- Protein interaction confidence
- 0.850371
- Protein interaction partners
- 89
- End position
- 4138932
- Start position
- 4094707
- Chromosome
- 11
- Strand
- Forward
- Cytoplasm.
- Cytosol
- Tissue specificity (tau)
- 0.815118
- Expression inequality (Gini)
- 0.346429
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 104.05
- Cells - Cultured fibroblasts
- 56.43
- Skin - Sun Exposed (Lower leg)
- 46.99
- Skin - Not Sun Exposed (Suprapubic)
- 42.36
- Vagina
- 32.76
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes104.05
- Cells - Cultured fibroblasts56.43
- Skin - Sun Exposed (Lower leg)46.99
- Skin - Not Sun Exposed (Suprapubic)42.36
- Vagina32.76
- Esophagus - Mucosa32.34
- Adrenal Gland31.31
- Artery - Tibial31.23
- Brain - Cerebellar Hemisphere27.61
- Cervix - Endocervix27.11
- Testis27.02
- Cervix - Ectocervix25.61
- Artery - Aorta25.59
- Bladder24.65
- Nerve - Tibial24.38
- Uterus24.11
- Ovary23.74
- Esophagus - Muscularis23.74
- Artery - Coronary23.13
- Esophagus - Gastroesophageal Junction22.93
- Fallopian Tube22.51
- Adipose - Subcutaneous22.44
- Brain - Cerebellum22.43
- Breast - Mammary Tissue21.71
- Colon - Sigmoid21.28
And 29 more, listed on the interactive page.
- GO:0006264
- GO:0006281
- GO:0009185
- GO:0009265
- GO:0010971
- GO:0070318
- GO:1900087
Cellular components
- GO:0005829
- GO:0005515
- GO:0042802
- GO:0061731
Related records
Trials (4,971)
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
- 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
- 2 Arm Study of Clofarabine IV in MDS Patients
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
- 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors
- 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
- 3-AP and Cytarabine in Treating Patients With Hematologic Cancer
- 3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
- 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
Drugs (10)
- Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor
- Fludarabine phosphate Ribonucleoside-diphosphate reductase RR1 inhibitor
- Gallium nitrate Ribonucleoside-diphosphate reductase RR1 inhibitor
- Gemcitabine Ribonucleoside-diphosphate reductase RR1 inhibitor
- Gemcitabine hydrochloride Ribonucleoside-diphosphate reductase RR1 inhibitor
- Hydroxyurea Ribonucleoside-diphosphate reductase RR1 inhibitor
- Motexafin gadolinium Ribonucleoside-diphosphate reductase RR1 inhibitor
- Tezacitabine Ribonucleoside-diphosphate reductase RR1 inhibitor
- Tezacitabine anhydrous Ribonucleoside-diphosphate reductase RR1 inhibitor
- Triapine Ribonucleotide reductase inhibitor